EXENS Stock Analysis: EXOSENS PROM | PA
Aerospace & Defense | PA, France | Market Cap: 3.085m EUR | 12M Return: 45.6% | FR001400Q9V2 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.70M
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Exosens is a French electro-optical technology company founded in 1937 and headquartered in Mérignac, France, operating through two main segments: Amplification and Detection & Imaging. The company manufactures image intensifier tubes, cameras, sensors, imaging modules, microchannel plates, Geiger-Müller tubes, gamma and neutron detectors, and silicon photodiodes, sold under brands such as Photonis, Xenics, Telops, El-Mul, and Noxant. Its products serve defense and surveillance, life sciences and environment, industrial control, and nuclear markets across France, Europe, North America, and Asia.
The company sits within the Industrials sector (Electrical Equipment & Parts) and supplies enabling components-rather than finished systems-to OEMs and integrators. Its electro-optical and radiation-detection products are used in applications such as night vision, missile warning, atmospheric sensing, and airborne methane detection, reflecting strong exposure to defense modernization and nuclear/radiological monitoring end-markets.
- Defense and surveillance backlog grows on elevated European NATO spending
- Detection and Imaging margins pressured by competition from L3Harris and Elbit
- Nuclear reactor buildout lifts demand for gamma and neutron detectors
| Net Income: 57.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.80 > 1.0 |
| NWC/Revenue: 35.37% < 20% (prev 43.78%; Δ -8.41% < -1%) |
| CFO/TA 0.13 > 3% & CFO 118.1m > Net Income 57.6m |
| Net Debt (180.9m) to EBITDA (162.2m): 1.12 < 3 |
| Current Ratio: 2.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.9m) vs 12m ago 0.29% < -2% |
| Gross Margin: 17.43% > 18% (prev 43.12%; Δ -25.69% > 0.5%) |
| Asset Turnover: 56.38% > 50% (prev 49.78%; Δ 6.60% > 0%) |
| Interest Coverage Ratio: 7.42 > 6 (EBIT TTM 86.4m / Interest Expense TTM 11.6m) |
| A: 0.20 (Total Current Assets 305.7m - Total Current Liabilities 130.0m) / Total Assets 895.0m |
| B: 0.11 (Retained Earnings 94.5m / Total Assets 895.0m) |
| C: 0.10 (EBIT TTM 86.4m / Avg Total Assets 881.2m) |
| D: 1.02 (Book Value of Equity 450.9m / Total Liabilities 444.2m) |
| Altman-Z'' = 3.36 = A |
| DSRI: 0.79 (Receivables 76.4m/83.9m, Revenue 496.8m/431.7m) |
| GMI: 2.47 (GM 43.12% / 17.43%) |
| AQI: 0.99 (AQ_t 0.50 / AQ_t-1 0.50) |
| SGI: 1.15 (Revenue 496.8m / 431.7m) |
| TATA: -0.07 (NI 57.6m - CFO 118.1m) / TA 895.0m) |
| Beneish M = -1.77 (Cap -4..+1) = CCC |
As of September 27, 2026, the stock is trading at EUR 62.30 with a total of 83,683 shares traded. Over the past week, the price has changed by +2.72%, over one month by +2.30%, over three months by +18.33% and over the past year by +45.55%.
Current recommended Stop Loss: 59.40 (which is 4.7% or 1.3 ATR below the current price).
EXOSENS PROM has no consensus analysts rating.
P/E Trailing = 90.8209
P/E Forward = 25.5102
P/S = 6.1478
P/B = 6.9
Revenue TTM = 496.8m EUR
EBIT TTM = 86.4m EUR
EBITDA TTM = 162.2m EUR
Long Term Debt = 249.3m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 5.30m EUR (from shortTermDebt, last quarter)
Debt = 286.1m EUR (from shortLongTermDebtTotal, last quarter) + Leases 16.6m
Net Debt = 180.9m EUR (calculated: Debt 286.1m - CCE 105.2m)
Enterprise Value = 3.27b EUR (3.08b + Debt 286.1m - CCE 105.2m)
Interest Coverage Ratio = 7.42 (Ebit TTM 86.4m / Interest Expense TTM 11.6m)
EV/FCF = 57.79x (Enterprise Value 3.27b / FCF TTM 56.5m)
FCF Yield = 1.73% (FCF TTM 56.5m / Enterprise Value 3.27b)
FCF Margin = 11.38% (FCF TTM 56.5m / Revenue TTM 496.8m)
Net Margin = 11.59% (Net Income TTM 57.6m / Revenue TTM 496.8m)
Gross Margin = 17.43% ((Revenue TTM 496.8m - Cost of Revenue TTM 410.2m) / Revenue TTM)
Gross Margin QoQ = 12.92% (prev 22.10%)
Tobins Q-Ratio = 3.65 (Enterprise Value 3.27b / Total Assets 895.0m)
Interest Expense / Debt = 4.07% (Interest Expense 11.6m / Debt 286.1m)
Taxrate = 23.22% (17.4m / 75.0m)
NOPAT = 66.3m (EBIT 86.4m * (1 - 23.22%))
Current Ratio = 2.35 (Total Current Assets 305.7m / Total Current Liabilities 130.0m)
Debt / Equity = 0.63 (Debt 286.1m / totalStockholderEquity, last quarter 450.9m)
Debt / EBITDA = 1.12 (Net Debt 180.9m / EBITDA 162.2m)
Debt / FCF = 3.20 (Net Debt 180.9m / FCF TTM 56.5m)
Total Stockholder Equity = 434.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.54% (Net Income 57.6m / Total Assets 895.0m)
RoE = 13.25% (Net Income TTM 57.6m / Total Stockholder Equity 434.7m)
RoCE = 12.63% (EBIT 86.4m / Capital Employed (Equity 434.7m + L.T.Debt 249.3m))
RoIC = 8.90% (NOPAT 66.3m / Invested Capital 745.5m)
WACC = 6.31% (E(3.08b)/V(3.37b) * Re(6.60%) + D(286.1m)/V(3.37b) * Rd(4.07%) * (1-Tc(0.23)))
Discount Rate = 6.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.11 | Cagr: 25.80%
[DCF] Terminal Value 77.97% ; FCFF base≈53.0m ; Y1≈60.8m ; Y5≈89.5m
[DCF] Fair Price = 23.00 (EV 1.35b - Net Debt 180.9m = Equity 1.17b / Shares 50.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 95.35 | Revenue CAGR: 33.58% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=1.91 | Chg30d=-1.06% | Revisions=+22% | GrowthEPS=+21.9% | GrowthRev=+18.4%
EPS next Year (2027-12-31): EPS=2.39 | Chg30d=+4.67% | Revisions=+44% | GrowthEPS=+25.2% | GrowthRev=+13.8%
[Analyst] Revisions Ratio: +40% (up=9, down=3)